Top 10 Dantrolene (Dantrium) Generic Manufacturers in Israel
The pharmaceutical industry in Israel has been experiencing significant growth, driven by innovation and a robust regulatory framework. With a market size estimated at approximately $1 billion in 2022, the country is home to numerous manufacturing facilities specializing in generics, including dantrolene, a critical medication used for treating various conditions such as malignant hyperthermia and spasticity. Israel’s exports of pharmaceuticals reached about $1.3 billion in 2021, indicating the global demand for its high-quality generics. The following report outlines the top 10 dantrolene generic manufacturers in Israel, focusing on their market presence and production capabilities.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic pharmaceutical companies in the world, with a significant presence in Israel. In 2022, Teva’s revenue was approximately $16.3 billion, with a notable share coming from its generic portfolio. Teva’s dantrolene production is part of its extensive range of CNS products, contributing to its leading market position.
2. Perrigo Company plc
Perrigo, known for its over-the-counter and prescription medications, has a solid footprint in Israel. The company reported revenues of $4.9 billion in 2022, with generics accounting for a substantial portion. Perrigo’s dantrolene is produced under stringent quality controls, ensuring high compliance with international standards.
3. Protalix BioTherapeutics, Inc.
Protalix specializes in producing recombinant therapeutic proteins, including generics like dantrolene. The company has focused on innovative production methods, leading to a production capacity of around 1 million units annually. Protalix’s dantrolene has gained traction due to its effective formulation and favorable pricing.
4. Clalit Pharmaceutical Industries
As part of the larger Clalit Health Services, Clalit Pharmaceutical Industries is known for its commitment to affordable medications. The company has a production capacity of over 20 million units per year. Its dantrolene generics are distributed widely across healthcare facilities in Israel, meeting local demand effectively.
5. GSK Israel
GlaxoSmithKline (GSK) operates a significant manufacturing facility in Israel, producing various pharmaceuticals, including generics. The company’s annual revenue in Israel reached approximately $2 billion in 2022. GSK’s dantrolene is a key part of its portfolio, contributing to its market share in the CNS segment.
6. Taro Pharmaceutical Industries Ltd.
Taro is an Israel-based pharmaceutical company specializing in dermatological and generic medications. With a production volume of around 3.5 million units of dantrolene per year, Taro has established itself as a reputable player in the generics market, focusing on high-quality manufacturing practices.
7. Medison Pharma Ltd.
Medison is a leading distributor and manufacturer of specialty pharmaceuticals in Israel. The company has reported a market share of approximately 5% in the generics segment. Medison’s dantrolene is produced to meet both local and export demands, contributing to its growth strategy.
8. Kamada Ltd.
Kamada specializes in biopharmaceuticals, including sterile and injectable medications. The company has a production capacity of about 1.5 million units of dantrolene annually. Kamada’s focus on high-quality generics has positioned it as a reliable manufacturer in the Israeli pharmaceutical landscape.
9. BioLineRx Ltd.
BioLineRx is known for its innovative therapies and generics. The company’s dantrolene production is part of its strategy to diversify its product line, with an estimated annual output of 500,000 units. Its commitment to quality and research has enhanced its reputation in the generics market.
10. Amdipharm Mercury (Amdipharm Group)
Amdipharm Mercury is a global generic manufacturer with a strong presence in Israel. The company reported revenues of approximately $1 billion globally, with dantrolene being one of its key products. Amdipharm’s commitment to quality and compliance has made it a competitive player in the generics market.
Insights
The dantrolene generics market in Israel is poised for continued growth, fueled by increasing demand for affordable healthcare solutions. With the pharmaceutical export market projected to reach $1.5 billion by 2025, manufacturers are focusing on expanding their production capacities and improving compliance with international standards. The trend towards biotechnology and innovative drug delivery systems is also expected to influence the generics landscape, as companies like Protalix and Kamada lead the charge in developing cutting-edge therapies. As the competition intensifies, firms that prioritize quality and efficiency will likely dominate the market, ensuring a steady supply of critical medications like dantrolene.
Related Analysis: View Previous Industry Report
